Comments for Oceanographer's Choice http://www.oceanographerschoice.com nekton, plankton, pings, and backscatter Sat, 04 Feb 2012 13:38:49 +0000 hourly 1 http://wordpress.org/?v=3.3.1 Comment on Russian Scientists to Sample Lake Vostok by Ltdumbear http://www.oceanographerschoice.com/2011/01/russian-scientists-to-sample-lake-vostok/comment-page-1/#comment-14942 Ltdumbear Sat, 04 Feb 2012 13:38:49 +0000 http://www.oceanographerschoice.com/?p=894#comment-14942 I hope you people know what you're doing. The Dinosaurs and other organisms who co-existed alongside them HAD thier time; they were selected for extinction for very REAL reasons. If you inadvertantly release 'something' into present-day the responsibility will be yours, and yours alone. On the flip-side of this, I hope your efforts will pave the way to exploring the oceans of distant planets and/or thier satellites. I have my fingers crossed and will be saying prayers for your success. I hope you people know what you’re doing. The Dinosaurs and other organisms who co-existed alongside them HAD thier time; they were selected for extinction for very REAL reasons. If you inadvertantly release ‘something’ into present-day the responsibility will be yours, and yours alone. On the flip-side of this, I hope your efforts will pave the way to exploring the oceans of distant planets and/or thier satellites. I have my fingers crossed and will be saying prayers for your success.

]]> Comment on In My Defense by Miriam Goldstein http://www.oceanographerschoice.com/2012/01/in-my-defense/comment-page-1/#comment-14512 Miriam Goldstein Tue, 24 Jan 2012 16:42:39 +0000 http://www.oceanographerschoice.com/?p=1326#comment-14512 Go Sam go! Go Sam go!

]]> Comment on Queensland Rain: Quick ‘n’ Dirty Climatology by crikey : Member of.. http:// www.theaustralianweatherforum.com http://www.oceanographerschoice.com/2011/01/queensland-rain-quick-n-dirty-climatology/comment-page-1/#comment-14044 crikey : Member of.. http:// www.theaustralianweatherforum.com Sun, 08 Jan 2012 10:13:32 +0000 http://www.oceanographerschoice.com/?p=916#comment-14044 Excellent presentation of your research. I wish all research was presented like this. l got the jist quite easily Now here's another one for you to calculate Is there a correlation between the length of time and /or magnitude in POS SOI and the rainfall anomaly. Thanks for your time on this l really enjoyed!! Excellent presentation of your research. I wish all research was presented like this.
l got the jist quite easily
Now here’s another one for you to calculate

Is there a correlation between the length of time and /or magnitude in POS SOI and the rainfall anomaly.
Thanks for your time on this l really enjoyed!!

]]> Comment on Phishy Conference by drB http://www.oceanographerschoice.com/2010/09/phishy-conference/comment-page-1/#comment-12478 drB Wed, 23 Nov 2011 21:44:42 +0000 http://www.oceanographerschoice.com/?p=649#comment-12478 I do not think these conferences are a scam. Rather, these are commercial enterprises trying to make money off participants by abnormally high registration fees and probably selling overpriced tours. Nothing wrong with that if it would be possible to opt out of their emails. I do not think these conferences are a scam. Rather, these are commercial enterprises trying to make money off participants by abnormally high registration fees and probably selling overpriced tours. Nothing wrong with that if it would be possible to opt out of their emails.

]]> Comment on The Joy of Fortran by Ioan Ferencik http://www.oceanographerschoice.com/2010/06/the-joy-of-fortran/comment-page-1/#comment-12212 Ioan Ferencik Tue, 15 Nov 2011 20:39:17 +0000 http://www.oceanographerschoice.com/?p=538#comment-12212 Interesting topic. I had my time with Fortran last winter, trying to port a hydraulic model to python(bindings). Do you mind sharing the fpy source? I am currently working with LiDAR data and your post gave me ideas. Regards Interesting topic. I had my time with Fortran last winter, trying to port a hydraulic model to python(bindings). Do you mind sharing the fpy source? I am currently working with LiDAR data and your post gave me ideas.
Regards

]]> Comment on Phishy Conference by Anonymous76 http://www.oceanographerschoice.com/2010/09/phishy-conference/comment-page-1/#comment-11314 Anonymous76 Fri, 14 Oct 2011 02:53:37 +0000 http://www.oceanographerschoice.com/?p=649#comment-11314 Hi all, I would like to add that I have been receiving similar emails for a cancer-related conference and was happy to come across this site to verify my sense that it wasn't legitimate - see below: BIT’s 5th Annual World Congress of Cancer 2012 Theme: Hand-in-Hand for Caring Time: May 18-20, 2012 Venue: Beijing, China Website: http://www.bitlifesciences.com/cancer2012/ I'm writing to follow-up my last invitation as below, would you please give me a tentative reply? Thank you very much. I apologize for the inconvenience if the letter disturbed you more than once. On behalf of the Meeting Organizing Committee, it is my pleasure and privilege to invite you to give a speech at BIT’s 5th Annual World Congress of Cancer 2012 with a theme of Hand-in-Hand for Caring. BIT Congress is proud to launch the 5th Anniversary of World Cancer Congress (WCC), which will be held from May 18 to May 20, 2012 in Beijing, China This is an invitation for you to join us in this congress. You can talk about Internet use leads cancer patients to be active health care consumers... at the IT171: Cancer Bioinformatics and Informatics under the Track 1: Breaking Cancer Research and Technology Innovations by submitting your speech title and CV to us. If the suggested thematic session is not your current focused core, you may look through the whole sessions and transfer another one that fit your interest(more info about the congress is available at http://www.bitlifesciences.com/cancer2012/). This Conference will continue the resounding success of the past conferences in Beijing and will provide a groundbreaking scientific program will draw together many cancer specialists from a wide range of disciplines from all over the world. Through this international congress it hopes to build upon and develop the great successes already achieved over the past few years. The congress theme of this year is "Hand-in-Hand for Caring" in keeping with the rapid growth and results in cancer research and care throughout the world. The 3-day diverse program has been designed to cover the breadth of oncology from cancer epidemiology and prevention, from drug discovery to cancer treatment and palliative care. It will also cover the main oncological aspects of these themes from molecular biology and genetics, to targeted therapies, innovation technology radiotherapy and imaging. The program is a very interesting mix of plenary lectures, the technical sessions, educational training courses, practical clinical case as well as industry supported symposia will provide delegates with information on the latest developments in basic science and clinical treatment. Several workshops and posters / papers session will be held concurrently to allow sharing of the excellent experience. The high profile speakers will provide productive form to greatly refresh the participant's knowledge and experience. Participants will enhance practical knowledge for everyday use and explore the most up-to-date information regarding the treatment of cancer. Please seize this wonderful opportunity and feel free to participate actively in all areas of the conference, I feel confident that you will enjoy both of the scientific program and the fine, traditional city of Beijing. To facilitate us to know your further interest, we appreciate your advices on: 1. Focused session and speech titles. 2. What’s your opinion to be the session chair/moderator? Further info about the program, please visit is available at http://www.bitlifesciences.com/cancer2012/fullprogram.asp Sincerely yours, Ms. Sherry Liu Organizing Committee of World Cancer Congress-2012 East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China Tel: 0086-411-84799609-822 Fax: 0086-411-84799629 Email: sherry@bitlifesciences.com Track 1: Breaking Cancer Research and Technology Innovations Section 1-1: Cancer Pathophysiology CP110: Mechanism of Metastasis and Invasion CP111: Formation of the Primary Tumor CP112: Progressive Growth and Angiogenesis CP113: Transport of Cancer ells CP114: Oncologic Emergencies CP115: Environmental Carcinogens CP116: Identification of Oncogenes and Cancers Section 1-2: Cancer Biomarkers CB120: Emerging Technologies for Cancer Biomarker Discovery and Assay DNA Microarray CB121: Genomic, Proteomic and Transcriptomic-based Biomarkers in Cancer CB122: Biomarkers for the Treatment and Progression of Cancers CB123: Biomarkers for the Prognosis of Cancers CB124: Methodologies and Applications of Cancer Biomarkers Section 1-3: Insight into Human Cancers MC1300: Cancer System Biology MC1301: Tumor Genetics and Cancer Epigenetics MS1302: Cancer Genomics, Genomic Instability, and Genome Surveillance MC1303: Cancer DNA Damage, DNA Repair, and Mitosis MC1304: Oncogenes, Tumor Suppressors, p53 and Regulation MC1305: Novel Pathways and Regulations of Cancers MC1306: Cancer/Tumor Adhesion, Migration, Invasion and Metastasis MC1307: Tumor Angiogenesis MC1308: Chromatin Regulation, Telomerase and Cancers MC1309: Interactions between Host and Tumor MC1310: Mitochondria and Cancer MC1311: Cancer Cell Cycle and Check Points MC1312: Tumor Microenvironment Interactions MC1313: Cancer Immunomodulation MC1314: Killing the Tumor Cell MC1315: Mechanisms of Drug Resistance and Tumor Microenvironment MC1316: Hematopoietic Growth Factors in Oncology MC1317: Cancer Profiling MC1318: Tumor Immunology and Immunotherapy MC1319: Molecular Pathology and Toxicology of Cancer Section 1-4: Circulating Tumor Cells CTC140: Emerging Technologies for CTC-based Cancer Detection CTC141: Biological and Molecular Characterization of CTCs CTC142: Molecular Signatures of CTCs CTC143: CTCs for Cancer Diagnosis, Prognosis and Treatment CTC144: Clinical Implications of CTCs Analysis on CTC-Tumor Relationship Section 1-5: Cancer Stem Cells CSC150: Molecular Biology of Cancer Stem Cells and Clinical Interrelationships CSC151: The Cancer Stem Cell Niche CSC152: Reprogramming and Plasticity of Cancer Stem Cells (CSCs) CSC153: Cancer Stem Cells Signaling Pathways and Implications CSC154: Breaking Research on Different Cancer Stem Cells Section 1-6: Metabolism and Cancer MC160: Studying Metabolism in Model Organism MC161: Stress Response and Metabolism Involved in Cancer MC162: Metabolic Influence of Epigenetics on Cancer MC163: Metabolism and Programmed Cell Death MC164: Metabolism, ER and Mitochondria Section 1-7: Innovative Technologies in Cancer Research IT170: Protein Chips, Tissue Chips, Lab-On-Chip and Microfluidic IT171: Cancer Bioinformatics and Informatics IT172: Animal Models and Mathematical Models IT173: Nanotechnology in Cancer Research Section 1-8: Translational Oncology TO180: Tumor Biomarkers in Clinical Trials TO181: Translation of Cancer Genomes and Integration of Cancer Omics Data TO182: Personalized Medicine for Cancers TO183: Developing Rational Strategies for Combination Therapy TO184: Novel Clinical Trial Design and Companion Diagnostics Track 2: Tobacco Control and Cancers TC200: Science, Policy and Public Health on Tobacco Control TC201: The Growing Tobacco Epidemic, Cancer Risks and Prevention TC202: Tobacco Carcinogenesis, Pharmacology, Mechanisms and Biomarkers TC203: Tobacco and Lung Cancer TC204: Tobacco Control Products and Treatment Track 3: Anticancer Drug Discovery -The Search for More Smart Drugs AD300: New Targets, New Technologies for Anticancer Therapeutics AD301: Drug Design and Lead Optimization AD302: High Throughput Screening: Targets, Assays, and Libraries AD303: Biomarker in Anticancer Drug Discovery AD304: Pharmacology, ADMET and Anticancer Drug Discover AD305: Targeting Angiogenesis AD306: Targeting Cancer Stem Cell Pathway AD307: Targeting Cell Cycle and Checkpoints AD308: Targeting DNA Damage Response, DNA Repair, Mitosis and Apoptosis AD309: Targeting Cancer Epigenetics and The Epigenome AD310: Targeting Nuclear Serine-Threonine Kinases AD311: Targeting PI3-Akt-mTOR Pathway and Other Protein Kinases AD312: Targeting Signaling Pathways and Signal Transduction AD313: Targeting Ubiquitin-related Pathway AD314: Targeting Tumor Necrosis Factor (TNF) and Chemokine Receptors AD315: Targeting Apoptotic Pathways for Novel Therapies in Cancer AD316: Targeting Wnt Signaling and Hedgehog Signaling Pathways AD317: Abl and bcr-abl Inhibition AD318: Telomerase Inhibition AD319: Inhibition of c-KIT AD320: Inhibition of Platelet-Derived Growth Factor Receptor (PDGFR) and VEGF AD321: Next Generation Proteasome Inhibitors AD322: Anticancer Monoclonal Antibody Discovery AD323: Anticancer Vaccine and Novel Adjuvant Approaches AD324: Gene Therapy, and RNAi based Anticancer Drug Discovery AD325: Anticancer Drug Discovery by Inhibition of Stem Cell Signaling AD326: Design New Molecules to Surpass Anticancer Drug Resistance AD327: Aurora Kinases and Their Inhibitors AD328: BRAF Targeted Therapy of Melanoma AD329: Targeting Cell Surface Proteins/Apoptosis AD330: Targeting Tumor Stroma Interaction AD331: T-Cell Therapies for Cancers AD332: Targeted Hormonal Therapies AD333: Targeting Tumor Metabolism AD334: Novel Cancer Drug Delivery Systems AD335: Update on Clinical Trials on Anticancer Therapeutics Track 4: Professional Networking Program PN 400: Meet-the-Expert-Tumor Biologists PN 401: Meet-the Expert-Tumor Immunologiests PN 402: Meet-the-Expert: Clinical Oncologists PN 403: Meet-the-Expert: Oncological Computation Experts PN 404: Meeting with Pioneers: Distinguished Leading Scientists PN 405: Meeting with Future Mentors: Learning the Graduate Study Programs PN 406: Meeting with Editors: How to Publish Your Research Results? PN 407: Meeting with Fund Managers: How to Write Your Successful Grant? PN408: Meeting with Successful CEOs: How to Succeed in Your Entrepreneurship PN 409: Career Advancement Tracks: Job Listing from Academia and Industries Track 5: Clinical Oncology and Medical Practice Section 5-1: Diagnosis and Prognosis of Cancers DP510: Imaging to Detect Recurrent Cancer DP511: Blood tests, Cancer Biomarkers for Molecular Diagnosis DP512: Proteomic Profiling for Cancer Diagnosis DP513: Real-time PCR and Amplification of Other Technologies DP514: Imaging and Diagnosis: X-Rays, MRI and MRCP, CT Scanning, PET and Ultrasound Section 5-2: Clinical Research on Cancers CT5200: Practical Cancer Chemotherapy CT5201: Radiotherapy and Medical Device Therapy for Cancer CT5202: Hormone Therapy in Cancer CT5203: Pharmacogenomics and Personalized Medicine CT5204: Sirtuins, Obesity, and Cancer CT5205: Cancer Surgery, and Symptom Management CT5206: Robotics and Tumor Mini-invasive Therapy CT5207: Botanical Medicine for Cancers in Clinical Practice CT5208: Integrative Medicine and Interventional Methods in Oncology CT5209: Systemic Treatment for Cancer CT5210: Clinical Development of Epidermal Growth Factor Receptor (EGFR) CT5211: Tyrosine Kinase Inhibitors: What Lessons Have We Learned? Section 5-3: Case Analysis on Diversified Cancers/Solid Tumors CR5300: Lung and Mediastinum Cancers CR5301: Breast Cancer CR5302: Esophageal/Stomach Cancer CR5303: Prostate Cancer CR5304: Colorectal Cancer, Colon, Rectal and Anal Cancer Management CR5305: Melanoma and Non-melanoma Skin Cancers CR5306: Kidney Cancer, Renal Cell Cancer and Adrenal Cancers CR5307: Head and Neck Cancers: Nasopharyngeal, Oral Cavity Cancers CR5308: Hematologic Malignancies CR5309: Bone, Sarcoma Cancers and Soft Tissue Cancers CR5310: Overian, Cervical, Vulva, Vagina, Uterine Malignancies and Endometrial Cancers CR5311: Neuroendocrine, CNS Tumors and Glioblastoma Section 5-4: Cancer Nursing and Support Care CN540: Oncology Nursing and Clinical Pain Management CN541: Palliative Care and Psycho-Oncology CN542: Quality of Life in Long-term Cancer Survivors CN543: Cancer Survivorship Research Track 6: Cancer Prevention, Epidemiology, and Public Health CP600: Cancer Genetics, Epidemiology, Biostatistics and Prevention CP601: Cancer Screening　, Monitoring, and Counseling for High-Risk Populations CP602: Food Carcinogen and Safety Control in Public Health CP603: Cancer Rehabilitation, Nutrition and Complementary Therapy CP604: Environment and Breast Cancer Hi all,

I would like to add that I have been receiving similar emails for a cancer-related conference and was happy to come across this site to verify my sense that it wasn’t legitimate – see below:

BIT’s 5th Annual World Congress of Cancer 2012

Theme: Hand-in-Hand for Caring

Time: May 18-20, 2012

Venue: Beijing, China

Website: http://www.bitlifesciences.com/cancer2012/

I’m writing to follow-up my last invitation as below, would you please give me a tentative reply? Thank you very much.

I apologize for the inconvenience if the letter disturbed you more than once. On behalf of the Meeting Organizing Committee, it is my pleasure and privilege to invite you to give a speech at BIT’s 5th Annual World Congress of Cancer 2012 with a theme of Hand-in-Hand for Caring.

BIT Congress is proud to launch the 5th Anniversary of World Cancer Congress (WCC), which will be held from May 18 to May 20, 2012 in Beijing, China

This is an invitation for you to join us in this congress. You can talk about Internet use leads cancer patients to be active health care consumers… at the IT171: Cancer Bioinformatics and Informatics under the Track 1: Breaking Cancer Research and Technology Innovations by submitting your speech title and CV to us. If the suggested thematic session is not your current focused core, you may look through the whole sessions and transfer another one that fit your interest(more info about the congress is available at http://www.bitlifesciences.com/cancer2012/).

This Conference will continue the resounding success of the past conferences in Beijing and will provide a groundbreaking scientific program will draw together many cancer specialists from a wide range of disciplines from all over the world.

Through this international congress it hopes to build upon and develop the great successes already achieved over the past few years. The congress theme of this year is “Hand-in-Hand for Caring” in keeping with the rapid growth and results in cancer research and care throughout the world. The 3-day diverse program has been designed to cover the breadth of oncology from cancer epidemiology and prevention, from drug discovery to cancer treatment and palliative care. It will also cover the main oncological aspects of these themes from molecular biology and genetics, to targeted therapies, innovation technology radiotherapy and imaging.

The program is a very interesting mix of plenary lectures, the technical sessions, educational training courses, practical clinical case as well as industry supported symposia will provide delegates with information on the latest developments in basic science and clinical treatment. Several workshops and posters / papers session will be held concurrently to allow sharing of the excellent experience. The high profile speakers will provide productive form to greatly refresh the participant’s knowledge and experience. Participants will enhance practical knowledge for everyday use and explore the most up-to-date information regarding the treatment of cancer.

Please seize this wonderful opportunity and feel free to participate actively in all areas of the conference, I feel confident that you will enjoy both of the scientific program and the fine, traditional city of Beijing.

To facilitate us to know your further interest, we appreciate your advices on:
1. Focused session and speech titles.

2. What’s your opinion to be the session chair/moderator?

Further info about the program, please visit is available at http://www.bitlifesciences.com/cancer2012/fullprogram.asp

Sincerely yours,

Ms. Sherry Liu

Organizing Committee of World Cancer Congress-2012

East Area, F11, Building 1,

Dalian Ascendas IT Park,

1 Hui Xian Yuan,

Dalian Hi-tech Industrial Zone,

LN 116025, China

Tel: 0086-411-84799609-822

Fax: 0086-411-84799629

Email: sherry@bitlifesciences.com

Track 1: Breaking Cancer Research and Technology Innovations

Section 1-1: Cancer Pathophysiology

CP110: Mechanism of Metastasis and Invasion

CP111: Formation of the Primary Tumor

CP112: Progressive Growth and Angiogenesis

CP113: Transport of Cancer ells

CP114: Oncologic Emergencies

CP115: Environmental Carcinogens

CP116: Identification of Oncogenes and Cancers

Section 1-2: Cancer Biomarkers

CB120: Emerging Technologies for Cancer Biomarker Discovery and Assay

DNA Microarray

CB121: Genomic, Proteomic and Transcriptomic-based Biomarkers in Cancer

CB122: Biomarkers for the Treatment and Progression of Cancers

CB123: Biomarkers for the Prognosis of Cancers

CB124: Methodologies and Applications of Cancer Biomarkers

Section 1-3: Insight into Human Cancers

MC1300: Cancer System Biology

MC1301: Tumor Genetics and Cancer Epigenetics
MS1302: Cancer Genomics, Genomic Instability, and Genome Surveillance

MC1303: Cancer DNA Damage, DNA Repair, and Mitosis
MC1304: Oncogenes, Tumor Suppressors, p53 and Regulation

MC1305: Novel Pathways and Regulations of Cancers

MC1306: Cancer/Tumor Adhesion, Migration, Invasion and Metastasis

MC1307: Tumor Angiogenesis

MC1308: Chromatin Regulation, Telomerase and Cancers

MC1309: Interactions between Host and Tumor

MC1310: Mitochondria and Cancer

MC1311: Cancer Cell Cycle and Check Points

MC1312: Tumor Microenvironment Interactions

MC1313: Cancer Immunomodulation

MC1314: Killing the Tumor Cell

MC1315: Mechanisms of Drug Resistance and Tumor Microenvironment

MC1316: Hematopoietic Growth Factors in Oncology

MC1317: Cancer Profiling

MC1318: Tumor Immunology and Immunotherapy

MC1319: Molecular Pathology and Toxicology of Cancer

Section 1-4: Circulating Tumor Cells

CTC140: Emerging Technologies for CTC-based Cancer Detection

CTC141: Biological and Molecular Characterization of CTCs

CTC142: Molecular Signatures of CTCs

CTC143: CTCs for Cancer Diagnosis, Prognosis and Treatment

CTC144: Clinical Implications of CTCs Analysis on CTC-Tumor Relationship

Section 1-5: Cancer Stem Cells

CSC150: Molecular Biology of Cancer Stem Cells and Clinical Interrelationships

CSC151: The Cancer Stem Cell Niche

CSC152: Reprogramming and Plasticity of Cancer Stem Cells (CSCs)

CSC153: Cancer Stem Cells Signaling Pathways and Implications

CSC154: Breaking Research on Different Cancer Stem Cells

Section 1-6: Metabolism and Cancer

MC160: Studying Metabolism in Model Organism

MC161: Stress Response and Metabolism Involved in Cancer

MC162: Metabolic Influence of Epigenetics on Cancer

MC163: Metabolism and Programmed Cell Death

MC164: Metabolism, ER and Mitochondria

Section 1-7: Innovative Technologies in Cancer Research

IT170: Protein Chips, Tissue Chips, Lab-On-Chip and Microfluidic

IT171: Cancer Bioinformatics and Informatics

IT172: Animal Models and Mathematical Models
IT173: Nanotechnology in Cancer Research

Section 1-8: Translational Oncology

TO180: Tumor Biomarkers in Clinical Trials

TO181: Translation of Cancer Genomes and Integration of Cancer Omics Data

TO182: Personalized Medicine for Cancers

TO183: Developing Rational Strategies for Combination Therapy

TO184: Novel Clinical Trial Design and Companion Diagnostics

Track 2: Tobacco Control and Cancers

TC200: Science, Policy and Public Health on Tobacco Control

TC201: The Growing Tobacco Epidemic, Cancer Risks and Prevention

TC202: Tobacco Carcinogenesis, Pharmacology, Mechanisms and Biomarkers

TC203: Tobacco and Lung Cancer

TC204: Tobacco Control Products and Treatment

Track 3: Anticancer Drug Discovery

-The Search for More Smart Drugs

AD300: New Targets, New Technologies for Anticancer Therapeutics

AD301: Drug Design and Lead Optimization

AD302: High Throughput Screening: Targets, Assays, and Libraries

AD303: Biomarker in Anticancer Drug Discovery

AD304: Pharmacology, ADMET and Anticancer Drug Discover

AD305: Targeting Angiogenesis

AD306: Targeting Cancer Stem Cell Pathway

AD307: Targeting Cell Cycle and Checkpoints

AD308: Targeting DNA Damage Response, DNA Repair, Mitosis and Apoptosis

AD309: Targeting Cancer Epigenetics and The Epigenome

AD310: Targeting Nuclear Serine-Threonine Kinases

AD311: Targeting PI3-Akt-mTOR Pathway and Other Protein Kinases

AD312: Targeting Signaling Pathways and Signal Transduction

AD313: Targeting Ubiquitin-related Pathway

AD314: Targeting Tumor Necrosis Factor (TNF) and Chemokine Receptors

AD315: Targeting Apoptotic Pathways for Novel Therapies in Cancer

AD316: Targeting Wnt Signaling and Hedgehog Signaling Pathways

AD317: Abl and bcr-abl Inhibition

AD318: Telomerase Inhibition

AD319: Inhibition of c-KIT

AD320: Inhibition of Platelet-Derived Growth Factor Receptor (PDGFR) and VEGF

AD321: Next Generation Proteasome Inhibitors

AD322: Anticancer Monoclonal Antibody Discovery

AD323: Anticancer Vaccine and Novel Adjuvant Approaches

AD324: Gene Therapy, and RNAi based Anticancer Drug Discovery

AD325: Anticancer Drug Discovery by Inhibition of Stem Cell Signaling

AD326: Design New Molecules to Surpass Anticancer Drug Resistance

AD327: Aurora Kinases and Their Inhibitors

AD328: BRAF Targeted Therapy of Melanoma

AD329: Targeting Cell Surface Proteins/Apoptosis

AD330: Targeting Tumor Stroma Interaction

AD331: T-Cell Therapies for Cancers

AD332: Targeted Hormonal Therapies

AD333: Targeting Tumor Metabolism

AD334: Novel Cancer Drug Delivery Systems

AD335: Update on Clinical Trials on Anticancer Therapeutics

Track 4: Professional Networking Program

PN 400: Meet-the-Expert-Tumor Biologists

PN 401: Meet-the Expert-Tumor Immunologiests

PN 402: Meet-the-Expert: Clinical Oncologists

PN 403: Meet-the-Expert: Oncological Computation Experts

PN 404: Meeting with Pioneers: Distinguished Leading Scientists

PN 405: Meeting with Future Mentors: Learning the Graduate Study Programs

PN 406: Meeting with Editors: How to Publish Your Research Results?

PN 407: Meeting with Fund Managers: How to Write Your Successful Grant?

PN408: Meeting with Successful CEOs: How to Succeed in Your Entrepreneurship

PN 409: Career Advancement Tracks: Job Listing from Academia and Industries

Track 5: Clinical Oncology and Medical Practice

Section 5-1: Diagnosis and Prognosis of Cancers

DP510: Imaging to Detect Recurrent Cancer

DP511: Blood tests, Cancer Biomarkers for Molecular Diagnosis

DP512: Proteomic Profiling for Cancer Diagnosis

DP513: Real-time PCR and Amplification of Other Technologies

DP514: Imaging and Diagnosis: X-Rays, MRI and MRCP, CT Scanning, PET and Ultrasound

Section 5-2: Clinical Research on Cancers

CT5200: Practical Cancer Chemotherapy

CT5201: Radiotherapy and Medical Device Therapy for Cancer

CT5202: Hormone Therapy in Cancer

CT5203: Pharmacogenomics and Personalized Medicine

CT5204: Sirtuins, Obesity, and Cancer

CT5205: Cancer Surgery, and Symptom Management

CT5206: Robotics and Tumor Mini-invasive Therapy

CT5207: Botanical Medicine for Cancers in Clinical Practice

CT5208: Integrative Medicine and Interventional Methods in Oncology

CT5209: Systemic Treatment for Cancer

CT5210: Clinical Development of Epidermal Growth Factor Receptor (EGFR)

CT5211: Tyrosine Kinase Inhibitors: What Lessons Have We Learned?

Section 5-3: Case Analysis on Diversified Cancers/Solid Tumors

CR5300: Lung and Mediastinum Cancers

CR5301: Breast Cancer

CR5302: Esophageal/Stomach Cancer

CR5303: Prostate Cancer

CR5304: Colorectal Cancer, Colon, Rectal and Anal Cancer Management

CR5305: Melanoma and Non-melanoma Skin Cancers

CR5306: Kidney Cancer, Renal Cell Cancer and Adrenal Cancers

CR5307: Head and Neck Cancers: Nasopharyngeal, Oral Cavity Cancers

CR5308: Hematologic Malignancies

CR5309: Bone, Sarcoma Cancers and Soft Tissue Cancers

CR5310: Overian, Cervical, Vulva, Vagina, Uterine Malignancies and Endometrial

Cancers

CR5311: Neuroendocrine, CNS Tumors and Glioblastoma

Section 5-4: Cancer Nursing and Support Care

CN540: Oncology Nursing and Clinical Pain Management

CN541: Palliative Care and Psycho-Oncology

CN542: Quality of Life in Long-term Cancer Survivors

CN543: Cancer Survivorship Research

Track 6: Cancer Prevention, Epidemiology, and Public Health

CP600: Cancer Genetics, Epidemiology, Biostatistics and Prevention

CP601: Cancer Screening　, Monitoring, and Counseling for High-Risk Populations

CP602: Food Carcinogen and Safety Control in Public Health

CP603: Cancer Rehabilitation, Nutrition and Complementary Therapy

CP604: Environment and Breast Cancer

]]> Comment on How to Kill a Young Albatross by sarah lytton http://www.oceanographerschoice.com/2010/01/how-to-kill-a-young-albatross/comment-page-1/#comment-11260 sarah lytton Tue, 11 Oct 2011 09:37:51 +0000 http://www.oceanographerschoice.com/?p=343#comment-11260 I am interested in trying to get people together who want to try and do something to stop this horrific situation. If anyone wants to contribute ideas that would be much appreciated. I am interested in trying to get people together who want to try and do something to stop this horrific situation. If anyone wants to contribute ideas that would be much appreciated.

]]> Comment on Krill v. Salps in the Southern Ocean by Joan http://www.oceanographerschoice.com/2010/03/krill-v-salps-in-the-southern-ocean/comment-page-1/#comment-10670 Joan Tue, 20 Sep 2011 19:41:13 +0000 http://www.oceanographerschoice.com/?p=478#comment-10670 We can only hope that the temperature stabilizes before it causes a more significant reduction in whale populations. Joan, <a href="http://www.neptunekrilloil.org" rel="nofollow">www.neptunekrilloil.org</a> We can only hope that the temperature stabilizes before it causes a more significant reduction in whale populations.

Joan,
http://www.neptunekrilloil.org

]]> Comment on Ice and Fire by Selena http://www.oceanographerschoice.com/2011/08/ice-and-fire/comment-page-1/#comment-10452 Selena Wed, 07 Sep 2011 06:57:08 +0000 http://www.oceanographerschoice.com/?p=1298#comment-10452 Man, now I want to go to Iceland. Man, now I want to go to Iceland.

]]> Comment on Where do hummingbirds go during a hurricane? by Emily http://www.oceanographerschoice.com/2011/08/where-do-hummingbirds-go-during-a-hurricane/comment-page-1/#comment-10329 Emily Wed, 31 Aug 2011 03:25:13 +0000 http://www.oceanographerschoice.com/?p=1308#comment-10329 Those little hummers are amazingly tough! As part of their yearly southward migration, Ruby-throated Hummingbirds fly non-stop over open water for 500 miles, across the Gulf of Mexico. To have enough energy to make it, they double their body mass (usually around 3 grams). Also, this bird tackled the hurricane head on: http://content.usatoday.com/communities/sciencefair/post/2011/08/bird-survive-rough-ride-through-hurricane-irene/1 Those little hummers are amazingly tough! As part of their yearly southward migration, Ruby-throated Hummingbirds fly non-stop over open water for 500 miles, across the Gulf of Mexico. To have enough energy to make it, they double their body mass (usually around 3 grams).

Also, this bird tackled the hurricane head on:
http://content.usatoday.com/communities/sciencefair/post/2011/08/bird-survive-rough-ride-through-hurricane-irene/1

]]>